Consolidators brace for decision on California’s controversial SB 977; Kohlberg makes big splash for Partners’ PCI Pharma

Blackstone Tactical Opportunities will be investing $275 million in Cryoport to support two new acquisitions in the cell and gene therapy supply chain.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this